Jul 2018 $2 M No. 4 Under $2 million 9
Marina Biotech, Inc.: Raise no. 4, Jul 2018 × Investors in this round 9 investors had bought by the notice of Jul 25, 2018: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $11 M offered; $9 M still to sell
Smallest investment taken $30,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $154,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Amit A. Shah · Executive Officer Erik A. Emerson · Executive Officer, Director Robert C. Moscato · Executive Officer, Director Donald A. Williams · Director Issac C. Blech · Director Tim A. Boris · Director Uli C. Hacksell · Director Vuong C. Trieu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in AL, CA, MD, MN, NC, NY, PA, WI, and outside the US Remarks in the notice On fees: “Maxim will also receive a warrant to purchase shares of common stock equal to 10% of the number of shares issuable upon conversion of the preferred stock sold in the offering, as well as additional commissions on any further sales in the offering.”On the use of proceeds: “A Portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”Signed by Robert C. Moscato, Jr., Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 25, 2018. Read the notice at the SEC .
equity, options SEC Apr 2018 $12 M No. 3 $10 to $50 million 97
Marina Biotech, Inc.: Raise no. 3, Apr 2018 × Investors in this round 97 investors had bought by the notice of Apr 26, 2018: 97 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $15 M offered; $3 M still to sell
Smallest investment taken $20,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,167,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Amit A. Shah · Executive Officer Joseph W. Ramelli · Executive Officer Vuong Trieu · Executive Officer, Director Donald A. Williams · Director Issac A. Blech · Director Philip C. Ranker · Director Philippe A. Calais · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “Maxim will also receive a warrant to purchase shares of common stock equal to 10% of the number of shares issuable upon conversion of the preferred stock sold in the offering. Maxim will receive additional commissions on any further sales in the offering.”On the use of proceeds: “A Portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”Signed by Vuong Trieu, Executive Chairman. Source: SEC Form D, newest notice filed Apr 26, 2018. Read the notice at the SEC .
equity, options SEC Aug 2015 $1 M No. 2 Under $2 million 3
Marina Biotech, Inc.: Raise no. 2, Aug 2015 × Investors in this round 3 investors had bought by the notice of Aug 12, 2015: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $100,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice J. Michael French · Executive Officer, Director Donald A. Williams · Director Joseph W. Ramelli · Director Philip C. Ranker · Director Stefan C. Loren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by J. Michael French, President and CEO. Source: SEC Form D, newest notice filed Aug 12, 2015. Read the notice at the SEC .
equity, options SEC Mar 2014 $6 M No. 1 $2 to $10 million 2
Marina Biotech, Inc.: Raise no. 1, Mar 2014 × Investors in this round 2 investors had bought by the notice of Mar 13, 2014: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken $500,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice J. Michael French · Executive Officer, Director Joseph W. Ramelli · Director Philip C. Ranker · Director Stefan C. Loren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by J. Michael French, President & CEO. Source: SEC Form D, newest notice filed Mar 13, 2014. Read the notice at the SEC .
equity, options SEC Jul 2010 $44 M Issued in a merger or acquisition $10 to $50 million 25
Marina Biotech, Inc.: Private sale, Jul 2010 × Investors in this round 25 investors had bought by the notice of Aug 5, 2010: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $44 M of $44 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $800,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Barry S. Polisky · Executive Officer J. Michael French · Executive Officer, Director Peter S. Garcia · Executive Officer Chiang J. Li · Director Gregory M. Sessler · Director James M. Karis · Director Michael D. Taylor · Director Peter D. Parker · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Canaccord Genuity Inc. (CRD 1020) · Boston, Massachusetts Sold in CA, MA, NC, NY Remarks in the notice On the amounts: “The Issuer issued 9,882,853 shares of Common Stock to the stockholders of Cequent Pharmaceuticals at an exchange ratio based on a value of the Common Stock equal to $1.1496.”On a merger: “The shares were issued in connection with the merger of Cequent Pharmaceuticals with and into a wholly-owned subsidiary of the Issuer.”Signed by Peter S. Garcia, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 5, 2010. Read the notice at the SEC .
equity SEC